NICM
SMMT icon

Neo Ivy Capital Management’s Summit Therapeutics SMMT Stock Holding History

Neo Ivy Capital Management’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-40,169
Closed -$855K – 520
2025
Q2 		$855K Buy
+40,169
New +$916K 0.27% 133
2025
Q1 		– Sell
-209,577
Closed -$3.74M – 409
2024
Q4 		$3.74M Buy
+209,577
New +$4.06M 0.75% 24

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
ACL
APEIRON Capital Ltd Hong Kong $107M AUM 9.59% 1-Year Est. Return

Neo Ivy Capital Management's SMMT Position: Q3 2025 in Review

Neo Ivy Capital Management sold out of Summit Therapeutics (SMMT) in Q3 2025, closing a stake of 40,169 shares — an estimated $855K sold.

Neo Ivy Capital Management first reported a position in SMMT in Q4 2024 and held it in 2 quarters. The position peaked at $3.74M in Q4 2024. 232 funds tracked by Wall St. Rank hold SMMT as of Q3 2025.

  • Neo Ivy Capital Management reported no remaining Summit Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Neo Ivy Capital Management sold 40,169 Summit Therapeutics shares in Q3 2025, an estimated $855K.
  • Neo Ivy Capital Management first reported a position in Summit Therapeutics in Q4 2024 and held it in 2 quarters.
  • Neo Ivy Capital Management's Summit Therapeutics position peaked at $3.74M in Q4 2024.
  • 232 funds tracked by Wall St. Rank held Summit Therapeutics as of Q3 2025.

Based on Neo Ivy Capital Management's 13F filing for Q3 2025, filed 12 Nov 2025.